Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-129.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -42.31% |
| Return on Assets (Trailing 12 Months) | -38.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 68.42M |
| Free Float | 55.15M |
| Market Capitalization | $362.63M |
| Average Volume (Last 20 Days) | 0.67M |
| Beta (Past 60 Months) | 2.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.78% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |